GlassScriptPhysician profile
Norma B Collie
NPI 1588061832
$6,920.61
in general payments reported to CMS, 2019-2025
40 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,221 · 2022: $4,497 · 2023: $64.08 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $202.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $976.49 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $651.29 | 2021-2022 | |
| Livanova USA, INC. | $634.35 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $627.93 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $433.48 | 2022 | |
| Ucb, INC. | $319.12 | 2021-2022 | |
| Eisai INC. | $291.28 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $269.27 | 2021 | |
| Jazz Pharmaceuticals INC. | $249.07 | 2022-2023 | |
| Lundbeck LLC | $241.53 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $213.22 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $206.98 | 2022-2023 | Trudhesa |
| Avanir Pharmaceuticals, INC. | $205.96 | 2021-2022 | |
| Sk Life Science, INC. | $202.55 | 2022 | |
| Amgen INC. | $188.30 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $160.47 | 2022 | |
| Genzyme Corporation | $110.97 | 2025 | |
| Biogen, INC. | $93.15 | 2021 | |
| Amneal Pharmaceuticals LLC | $89.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $75.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.37 | 2021-2022 | |
| Csl Behring | $68.51 | 2021-2022 | |
| Argenx US, INC. | $58.44 | 2022 | |
| Tanabe Pharma America, INC. | $52.61 | 2022 | |
| Medtronic, INC. | $45.00 | 2021 | |
| Adamas Pharmaceuticals, INC. | $40.33 | 2021 | |
| Kyowa Kirin, INC. | $37.45 | 2022 | |
| Idorsia Pharmaceuticals US INC | $36.43 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $35.59 | 2021 | |
| Lilly USA, LLC | $34.11 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $33.18 | 2021 | |
| Mdd US Operations, LLC | $28.65 | 2022 | |
| Tersera Therapeutics LLC | $23.89 | 2022 | |
| Corium, LLC | $22.88 | 2022 | |
| Acorda Therapeutics, INC | $22.62 | 2022 | |
| Acadia Pharmaceuticals INC | $20.63 | 2021 | |
| Abbott Laboratories | $17.32 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.91 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.42 | 2021 | |
| Grt US Holding, INC. | $6.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Collie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.